FRAT2, a regulator of the Wnt signaling pathway [18], was negatively correlated with the S:E fusion-positive group, but it was significantly highly expressed compared with normal prostate tissue (Figure S4), suggesting that it might be a good therapeutic target for prostate cancer but not for the S:E fusion-positive group specifically. This evidence concerns the gene FRAT2 and prostate cancer.